GlaxoSmithKline (GSK)'s Ebola Vaccine To Be Tested For Safety In Humans As Early As Next Week

U.S. scientists will begin enrolling patients as soon as next week in clinical safety trials of GlaxoSmithKline Plc (GSK)’s experimental Ebola vaccine as the death toll from the disease rises in West Africa.

The National Institutes of Health’s Vaccine Research Center received approval from the Food and Drug Administration to start the Phase 1 trial, Michael Kurilla, director of the Office of Biodefense, Research Resources and Translational Research, said today in a telephone interview. A Phase 1 trial is the first test of a drug or vaccine in humans to assess safety and whether it works similarly to how it does in animals.